

**Supplemental Table 4: Treatment Emergent Adverse Events Attributed to Pembrolizumab, Any Grade.**

	<b>n</b>	<b>%</b>
<b><i>At least one Pembrolizumab-related AE</i></b>	<b>20</b>	<b>66.7%</b>
Diarrhea	9	30.0%
Fatigue	7	23.3%
Arthralgia	6	20.0%
Hypothyroidism	5	16.7%
Hyperthyroidism	3	10.0%
Nausea	3	10.0%
Pain in extremity	3	10.0%
Generalized muscle weakness	3	10.0%
Alkaline phosphatase increased	2	6.7%
Arthritis	2	6.7%
Colitis	2	6.7%
Creatinine increased	2	6.7%
Lipase increased	2	6.7%
Musculoskeletal and connective tissue disorder - Other	2	6.7%
Myalgia	2	6.7%
Serum amylase increased	2	6.7%
Autoimmune disorder	2	6.7%
Abdominal pain	1	3.3%
Alanine aminotransferase increased	1	3.3%
Aspartate aminotransferase increased	1	3.3%
Back pain	1	3.3%
Blood bilirubin increased	1	3.3%
Bone pain	1	3.3%
Cardiac disorders - Other	1	3.3%
Chills	1	3.3%
Constipation	1	3.3%
Cough	1	3.3%
Dizziness	1	3.3%
Dry mouth	1	3.3%
Dry skin	1	3.3%
Fever	1	3.3%
Flank pain	1	3.3%
Gastritis	1	3.3%
Gastrointestinal disorders - Other	1	3.3%
Hirsutism	1	3.3%
Hyperglycemia	1	3.3%
Hypokalemia	1	3.3%
Hyponatremia	1	3.3%
Hypotension	1	3.3%
Infections and infestations - Other	1	3.3%

Malaise	1	3.3%
Mucositis oral	1	3.3%
Pancreatitis	1	3.3%
Pruritus	1	3.3%
Skin and subcutaneous tissue disorders - Other	1	3.3%
Stomach pain	1	3.3%
Watering eyes	1	3.3%
Edema limbs	1	3.3%